[Ventricular arrhythmias in myocardial ischemia].
Multicentre trials have shown that the decision to start antiarrhythmic therapy must be critically discussed. Diagnostic tests to establish a risk of sudden death in the patient are of value. The obtained results of tests should help to determine whether antiarrhythmic drugs should be given. According to the majority of investigators, a complex arrhythmias, mainly class IVb, should be treated. If it possible, arrhythmogenic substance should be removed. In case of pharmacotherapy, it is recommended to start with beta-adrenolytics, if there are no contraindications. If this therapy fails, drugs of group I should be given. Amiodarone should be tried as the last antiarrhythmic agent in life-threatening cardiac arrhythmias.
Byrczek
M
M
Oddziału Chorób Wewnetrznych Szpitala Miejskiego Nr 1 w Rybniku.
D000638:Amiodarone / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D017202:Myocardial Ischemia / Q000150:complications*
D000638:Amiodarone
Komorowe zaburzenia rytmu w chorobie niedokrwiennej serca.